Melanoma Risk Variants Prevent MC1R Palmitoylation and Activation [Melanoma]
Palmitoylation-deficient MC1R variants accelerate BRAFV60E-driven melanomagenesis. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Melanoma Source Type: research
METTL3 Increases m6A to Block Differentiation and Promote Leukemogenesis [Leukemia]
METTL3 is upregulated in acute myeloid leukemia compared with other tumors and normal HSPCs. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Leukemia Source Type: research
The EGFR-AS1 Long Noncoding RNA Modulates EGFR TKI Sensitivity [Kinase Inhibitors]
A synonymous EGFR mutation promotes TKI response by reducing EGFR-AS1 levels in squamous-cell cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Kinase Inhibitors Source Type: research
Targeting the c-Rel Subunit of NF-{kappa}B Inhibits Treg Function in Melanoma [Immunology]
Specific inhibition of c-Rel impairs activated Tregs to suppress melanoma growth in vivo. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Immunology Source Type: research
First-Line Dabrafenib plus Trametinib Has Activity in BRAFV600E NSCLC [Clinical Trials]
Dabrafenib plus trametinib achieves responses in 64% of patients with metastatic BRAFV600E NSCLC. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
Glioblastoma Stem Cell Clonal Dynamics Drive Intratumor Heterogeneity [Brain Tumors]
GBM heterogeneity is primarily driven by the stochastic outcome of GBM stem cell hierarchical growth. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Brain Tumors Source Type: research
WNT and SHH Drive the Tumorigenesis of a Rare Embryonal Brain Tumor [Brain Tumors]
Coexpression of Wnt and Shh in Sox2+/Pax6+ apical radial glia in the VZ drives ETMR formation in vivo. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Brain Tumors Source Type: research
The Splicing Regulator PRMT5 Is Critical for Glioblastoma Proliferation [Brain Tumors]
PRMT5 regulates the splicing of detained introns in proliferation-associated genes in GBM. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Brain Tumors Source Type: research
PPARG-Activated Bladder Cancer Cells Exhibit a PPARG Dependency [Bladder Cancer]
PPARG-selective inverse agonists can suppress proliferation in PPARG-activated bladder cancer cells. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Bladder Cancer Source Type: research
Melanoma Drugs Effective as Adjuvants [News in Brief]
BRAF-targeted strategies and PD-1–blocking immunotherapy are more effective adjuvant therapies than currently approved options for patients with high-risk resectable melanoma. However, choosing the best agent for patients with BRAF-mutated disease remains a challenge. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
First-Line Abemaciclib Effective in ER+ Breast Cancer [News in Brief]
Interim data from the MONARCH3 study indicate that abemaciclib is an effective first-line therapy for advanced ER-positive, HER2-negative breast cancer. Adding the investigational CDK4/6 inhibitor to letrozole significantly improved patients' progression-free survival, compared with those given a placebo alongside endocrine therapy. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Checkpoint Inhibitor Combo Effective for RCC [News in Brief]
In a phase III trial, the combination of nivolumab and ipilimumab yielded more and longer responses than sunitinib in patients with renal cell carcinoma at intermediate or high risk of progression. More than 41% of patients who received the immunotherapy combination responded, compared with 26.5% of patients who received sunitinib. Patients receiving the combination also experienced longer progression-free survival and fewer side effects. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Durvalumab Promising for NSCLC [News in Brief]
The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non–small cell lung cancer, according to interim results of a phase III trial. The benefit was great enough that the drug could become the standard of care in the United States for these patients. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Nivolumab Approved for Liver Cancer [News in Brief]
The FDA granted accelerated approval to nivolumab for second-line treatment of advanced hepatocellular carcinoma, making it just the third drug on the market for the disease. The PD-1 inhibitor is approved for patients who cannot tolerate sorafenib and those whose disease progressed despite treatment with the multikinase inhibitor. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Targeting Angiogenesis in Bladder Cancer [News in Brief]
Findings from the phase III RANGE study indicate that adding ramucirumab to docetaxel may improve progression-free survival for patients with advanced or metastatic urothelial carcinoma whose disease is refractory to platinum chemotherapy. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
